Your browser doesn't support javascript.
loading
The effects of citalopram, SB-334867 and orexin-1, alone or in various combinations, on the anxiogenic-like effects of REM sleep deprivation in male mice.
Saadati, Naghmeh; Bananej, Maryam; Khakpai, Fatemeh; Zarrindast, Mohammad-Reza; Alibeik, Hengameh.
  • Saadati N; Department of Biology, Faculty of Biological Sciences, North Tehran Branch.
  • Bananej M; Department of Biology, Faculty of Biological Sciences, North Tehran Branch.
  • Khakpai F; Department of Physiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University.
  • Zarrindast MR; Department of Pharmacology, School of Medicine.
  • Alibeik H; Iranian National Center for Addiction Studies.
Behav Pharmacol ; 33(8): 559-566, 2022 12 01.
Article en En | MEDLINE | ID: mdl-36165531
Sleep deprivation may induce anxiety. On the other hand, anxiety disorders elicit main changes in the quality of sleep. Moreover, orexin and citalopram play a role in the modulation of insomnia and mood diseases. Thus, we planned preclinical research to evaluate the effect of combinations of orexin agents and citalopram on anxiety behavior in rapid eye movement (REM) sleep-deprived mice. For drug intracerebroventricular (i.c.v.) infusion, the guide cannula was surgically implanted in the left lateral ventricle of mice. REM sleep deprivation was conducted via water tank apparatus for 24 h. The anxiety behavior of mice was evaluated using the elevated plus maze (EPM). Our results revealed that REM sleep deprivation reduced the percentage of open arm time (%OAT) and the percentage of the open arm entries (%OAE) but not closed arm entries (locomotor activity) in the EPM test, presenting an anxiogenic response ( P < 0.05). We found a sub-threshold dose of SB-334867, orexin-1 receptor antagonist, and orexin-1 which did not alter anxiety reaction in the REM sleep-deprived mice ( P > 0.05). Intraperitoneal (i.p.) injections of citalopram (5 and 10 mg/kg) increased both %OAT and %OAE ( P < 0.001) representing an anxiolytic effect, but not locomotor activity in the REM sleep-deprived mice. Interestingly, co-treatment of citalopram (1, 5 and 10 mg/kg; i.p.) and SB-334867 (0.1 µg/mouse; i.c.v.) potentiated the anxiolytic effect in the REM sleep-deprived mice. On the other hand, co-treatment of different dosages of citalopram along with a sub-threshold dose of orexin-1 did not alter %OAT, %OAE, and locomotor activity in the REM sleep-deprived mice. We found a synergistic anxiolytic effect of citalopram and SB-334867 in the REM sleep-deprived mice. These results suggested an interaction between citalopram and SB-334867 to prevent anxiogenic behavior in the REM sleep-deprived mice.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ansiolíticos / Citalopram Límite: Animals Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ansiolíticos / Citalopram Límite: Animals Idioma: En Año: 2022 Tipo del documento: Article